UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment

Journal of medicinal chemistry, 2015-02, Vol.58 (3), p.1038-1052

2015

Volltextzugriff (PDF)

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

Annual review of pharmacology and toxicology, 2009-01, Vol.49 (1), p.223-241

2009

Volltextzugriff (PDF)

Targeting Apoptosis Pathways for New Cancer Therapeutics

Annual review of medicine, 2014-01, Vol.65 (1), p.139-155

2014

Volltextzugriff (PDF)

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Journal of medicinal chemistry, 2020-07, Vol.63 (14), p.7510-7528

2020

Volltextzugriff (PDF)

Targeting the MDM2-p53 Interaction for Cancer Therapy

Clinical cancer research, 2008-09, Vol.14 (17), p.5318-5324

2008

Volltextzugriff (PDF)

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.941-964

2019

Volltextzugriff (PDF)

A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo

Neoplasia (New York, N.Y.), 2020-10, Vol.22 (10), p.522-532

2020

Volltextzugriff (PDF)

Therapeutic Strategies to Activate p53

Pharmaceuticals (Basel, Switzerland), 2022-12, Vol.16 (1), p.24

2022

Volltextzugriff (PDF)

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.448-466

2019

Volltextzugriff (PDF)

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells

Neoplasia (New York, N.Y.), 2016-03, Vol.18 (3), p.162-171

2016

Volltextzugriff (PDF)

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Nature (London), 2014-06, Vol.510 (7504), p.278-282

2014

Volltextzugriff (PDF)

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Journal of medicinal chemistry, 2018-08, Vol.61 (15), p.6685-6704

2018

Volltextzugriff (PDF)

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Journal of medicinal chemistry, 2019-12, Vol.62 (24), p.11280-11300

2019

Volltextzugriff (PDF)

On-Wafer Microstrip Meander-Line Slow-Wave Structure at Ka-Band

IEEE transactions on electron devices, 2018-06, Vol.65 (6), p.2142-2148

2018

Volltextzugriff (PDF)

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

Neoplasia (New York, N.Y.), 2020-02, Vol.22 (2), p.111-119

2020

Volltextzugriff (PDF)

The Making of I‑BET762, a BET Bromodomain Inhibitor Now in Clinical Development

Journal of medicinal chemistry, 2013-10, Vol.56 (19), p.7498-7500

2013

Volltextzugriff (PDF)

Complex Permittivity Characterization of Liquid Samples Based on a Split Ring Resonator (SRR)

Sensors (Basel, Switzerland), 2021-05, Vol.21 (10), p.3385

2021

Volltextzugriff (PDF)

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

Journal of medicinal chemistry, 2013-07, Vol.56 (13), p.5553-5561

2013

Volltextzugriff (PDF)

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer

Cell reports (Cambridge), 2018-02, Vol.22 (9), p.2236-2245

2018

Volltextzugriff (PDF)

The Ecstasy and Agony of Assay Interference Compounds

Journal of medicinal chemistry, 2017-03, Vol.60 (6), p.2165-2168

2017

Volltextzugriff (PDF)

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

Journal of the American Chemical Society, 2013-01, Vol.135 (2), p.669-682

2013

Volltextzugriff (PDF)

Wideband Power Combining of Four Microfabricated W-Band Traveling-Wave Tubes

IEEE transactions on electron devices, 2017-09, Vol.64 (9), p.3849-3856

2017

Volltextzugriff (PDF)

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

Neoplasia (New York, N.Y.), 2022-07, Vol.29, p.100798-100798, Article 100798

2022

Volltextzugriff (PDF)

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Nature communications, 2017-10, Vol.8 (1), p.1150-12, Article 1150

2017

Volltextzugriff (PDF)

Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia

Molecular cell, 2014-01, Vol.53 (2), p.247-261

2014

Volltextzugriff (PDF)

1 – 25 von 956

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(789)
Mit Volltextzugriff
(817)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(607)
Life Sciences & Biomedicine
(362)
Humans
(237)
Physical Sciences
(208)
Pharmacology & Pharmacy
(198)
Chemistry, Medicinal
(176)
Technology
(158)
Animals
(148)
Chemistry
(127)
Biological And Medical Sciences
(117)
Cell Line, Tumor
(117)
Medical Sciences
(105)
Engineering
(101)
Mice
(97)
Pharmacology. Drug Treatments
(88)
Physics
(87)
Models, Molecular
(84)
Antineoplastic Agents - Pharmacology
(78)
Oncology
(77)
Structure-Activity Relationship
(77)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy

Targeting Apoptosis Pathways for New Cancer Therapeutics

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Targeting the MDM2-p53 Interaction for Cancer Therapy

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo

Therapeutic Strategies to Activate p53

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

On-Wafer Microstrip Meander-Line Slow-Wave Structure at Ka-Band

Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

The Making of I‑BET762, a BET Bromodomain Inhibitor Now in Clinical Development

Complex Permittivity Characterization of Liquid Samples Based on a Split Ring Resonator (SRR)

A Potent Small-Molecule Inhibitor of the MDM2–p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer

The Ecstasy and Agony of Assay Interference Compounds

High-Affinity, Small-Molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein–Protein Interaction

Wideband Power Combining of Four Microfabricated W-Band Traveling-Wave Tubes

Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia

Suchergebnisse filtern